Vienna - Delayed Quote • EUR Pharma Mar, S.A. (PHM.VI) Follow Compare 88.60 +2.55 +(2.96%) At close: 3:30:34 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations 3 Growth Stocks With Insider Ownership Expecting Up To 71% Earnings Growth As global markets experience a rebound fueled by easing core U.S. inflation and strong bank earnings, the focus has shifted to how growth stocks are navigating these conditions. In this environment, companies with substantial insider ownership often attract attention due to their potential alignment of interests between management and shareholders, suggesting confidence in the company's future prospects. High Growth Tech Stocks To Watch In January 2025 As global markets navigate a choppy start to the year, with small-cap stocks underperforming and inflation concerns persisting, investors are closely watching economic indicators and policy updates that could influence market sentiment. In such an environment, identifying high-growth tech stocks requires careful consideration of their potential to innovate and adapt amidst economic uncertainties. 3 Stocks Estimated To Be Up To 48% Below Intrinsic Value As global markets navigate a mixed start to the new year, with U.S. stocks closing out a strong 2024 despite some recent volatility, investors are keenly observing economic indicators like the Chicago PMI and GDP forecasts for signs of future trends. In this environment of fluctuating indices and economic uncertainty, identifying undervalued stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to optimize their portfolios. Insider-Led Growth Stocks To Watch In December 2024 As global markets navigate the complexities of interest rate adjustments and political uncertainties, investors are closely watching how these factors impact major indices. Despite recent declines in U.S. stocks and broader market volatility driven by cautious Fed commentary, opportunities for growth remain, particularly in companies with strong insider ownership that can leverage their leadership's vested interests to drive long-term success. In such an environment, stocks led by insiders... High Growth Tech Stocks With Promising Potential As global markets navigate a landscape marked by record highs in major indexes like the S&P 500 and Nasdaq Composite, contrasted with declines in the Russell 2000, growth stocks have notably outperformed their value counterparts. In this environment of mixed economic indicators and geopolitical developments, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation potential and resilience amidst market fluctuations. 3 Stocks Estimated To Be Trading At Up To 49.2% Below Intrinsic Value As global markets continue to reach record highs, driven by domestic policy shifts and geopolitical developments, investors are increasingly focused on finding value amidst the bullish trends. In such an environment, identifying stocks that are trading below their intrinsic value can offer opportunities for potential growth and stability. 3 Insider-Favored Growth Companies To Watch As global markets experience broad-based gains with U.S. indexes approaching record highs, investor sentiment is buoyed by strong labor market reports and stabilizing economic conditions. In this environment, growth companies with high insider ownership are particularly intriguing as they often indicate confidence from those closest to the business, potentially aligning well with the current market optimism. High Growth Tech Stocks To Watch In The Current Market Amidst a backdrop of global market optimism fueled by expectations of economic growth and tax reforms following the recent U.S. election, major indices like the small-cap Russell 2000 have experienced significant gains, reflecting investor confidence in potentially favorable business conditions. In this environment, identifying promising high-growth tech stocks involves focusing on companies with innovative solutions and strong adaptability to evolving market dynamics. Pharma Mar SA Reports Strong Revenue Growth in 2024 Pharma Mar SA ( (PHMMF) ) has released its Q3 earnings. Here is a breakdown of the information Pharma Mar SA presented to its investors. Pharma Mar SA is a biotechnology company based in Madrid, Spain, specializing in the development of innovative oncology therapies. The company is known for its research-intensive approach, focusing on marine-derived compounds for cancer treatment. In its latest earnings report for the first nine months of 2024, Pharma Mar SA reported a revenue increase of 8% ye 3 Growth Stocks With High Insider Ownership And Earnings Up To 55% As global markets navigate a complex landscape marked by interest rate adjustments and sector-specific shifts, the U.S. indices have shown resilience with notable performances in mid-cap and small-cap segments. Amidst these developments, identifying growth stocks with high insider ownership can be particularly appealing, as such companies often demonstrate strong alignment between management and shareholder interests, potentially enhancing their capacity for sustained growth in fluctuating... High Growth Tech Highlights Three Promising Stocks As global markets experience fluctuations, with U.S. indices reaching new highs amid mixed economic signals and inflation concerns, the tech sector continues to capture attention due to its potential for rapid growth and innovation. In this context, identifying promising stocks involves evaluating companies that not only demonstrate strong earnings prospects but also possess the agility to navigate evolving market dynamics effectively. PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer PharmaMar (MSE: PHM) and its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ) have announced today positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage Small Cell Lung Cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of lurbine September 2024's Top Growth Picks With High Insider Ownership As global markets show signs of recovery, with U.S. stocks rebounding and growth stocks outperforming value shares, the focus on companies with strong insider ownership becomes increasingly relevant. High insider ownership often signals confidence in a company's future prospects, making these firms particularly attractive during periods of market optimism and economic adjustments. 3 Growth Stocks With Insider Ownership Up To 14% In the midst of a global market recovery, U.S. stocks have shown solid gains, particularly in the technology sector, bolstering hopes for a "soft landing" for the economy. As growth stocks continue to outpace value shares, it's crucial to identify companies with strong insider ownership as this often signals confidence from those closest to the business. When evaluating growth stocks in today's market environment, high insider ownership can be an important indicator of potential success and... 3 Growth Companies With High Insider Ownership And Up To 23% Revenue Growth As global markets exhibit mixed signals with the S&P 500 reaching new highs and sectors like technology leading the charge, investors are navigating through a landscape shaped by fluctuating interest rates and economic indicators. In such a market, growth companies with high insider ownership can be particularly compelling, as this combination often signals strong confidence in the company’s future from those who know it best. Exploring Three Growth Companies Where Insiders Hold The Reins As global markets navigate through a landscape marked by fluctuating inflation rates and shifting monetary policies, investors are keenly observing the impact on various stock sectors. In this environment, growth companies with high insider ownership can offer unique advantages, as insiders' substantial equity stakes often align their interests closely with those of shareholders, potentially fostering robust governance and strategic consistency amidst market volatility. PharmaMar presents encouraging results at ASCO for Small Cell Lung Cancer PharmaMar (MSE: PHM), world leader in the discovery, development and commercialization of marine-derived cancer treatments, presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States. Performance Overview Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is IBEX 35... Return PHM.VI IBEX 35... YTD +15.97% +7.21% 1-Year +118.46% +23.20% 3-Year +35.31% +43.66%